Lung Cancer

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab injection for use in combination with erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Osimertinib, at 160 mg daily, demonstrated efficacy in the central nervous system and a manageable safety profile in patients with EGFR-mutant advanced non–small cell lung cancer who have leptomeningeal metastases.

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for single-agent atezolizumab as a frontline treatment for patients with advanced nonsquamous or squamous non–small cell lung cancer without EGFR or ALK mutations who have high PD-L1 expression on tumor cells or tumor-infiltrating immune cells, defined as TC3/IC3 wild-type.

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.

Thomas J. Lynch Jr, MD, discusses his journey in the field of oncology, his transition to Fred Hutchinson Cancer Research Center, and his goals for the institution going forward.

The FDA has granted a priority review designation to a new drug application for lurbinectedin as a treatment for patients with small cell lung cancer who have progressed following platinum-containing therapy.

A high body mass index at baseline may be independently associated with improved survival outcomes in patients with non–small cell lung cancer who receive immune checkpoint inhibitor therapy.

Patients with high-risk lung cancer who underwent volume CT screening had a significantly lower lung cancer mortality compared with those who were not screened.

The FDA has granted a priority review designation to a new drug application for capmatinib for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping—mutated non–small cell lung cancer.

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

The FDA has granted a final approval to pemetrexed for injection, an alternative to standard pemetrexed, for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.